About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Ndrg2tm1Kmori
targeted mutation 1, Kazuhiro Morishita
MGI:5617965
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Ndrg2tm1Kmori/Ndrg2tm1Kmori involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj MGI:5699402
ht2
 		Ndrg2tm1Kmori/Ndrg2+ involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj MGI:5699403


Genotype
MGI:5699402
hm1
Allelic
Composition		 Ndrg2tm1Kmori/Ndrg2tm1Kmori
Genetic
Background		 involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndrg2tm1Kmori mutation (0 available); any Ndrg2 mutation (27 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
decreased survivor rate ( J:210264 )
• survival rate is already reduced by ~10% at 10 months, and subsequently declines after ~15 months of age
• less than 40% of homozygotes survive to 24 months of age
premature death ( J:210264 )
• although born at normal Mendelian ratios and without any obvious physical abnormalities, homozygotes exhibit a significantly shorter lifespan than wild-type or heterozygous mutant mice

neoplasm
increased tumor incidence ( J:210264 )
• 75% of homozygotes exhibit spontaneous tumor development of various types, including T-cell lymphomas, relative to 26.7% in wild-type controls
increased T cell derived lymphoma incidence ( J:210264 )
• 58.3% of homozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype
increased hepatocellular carcinoma incidence ( J:210264 )
• 8.3% of homozygotes develop hepatic cancer relative to 0% (none) in wild-type controls
increased lung carcinoma incidence ( J:210264 )
• 8.3% of homozygotes develop lung cancer relative to 6.7% in wild-type controls

cellular
increased fibroblast proliferation ( J:210264 )
• homozygous mutant MEFs show increased phosphorylated PTEN-Ser380/Thr382/Thr383, high AKTSer473 phosphorylation, and significantly increased cell proliferation relative to wild-type or heterozygous mutant MEFs

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:210264 )
• 58.3% of homozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype

liver/biliary system
increased hepatocellular carcinoma incidence ( J:210264 )
• 8.3% of homozygotes develop hepatic cancer relative to 0% (none) in wild-type controls

respiratory system
increased lung carcinoma incidence ( J:210264 )
• 8.3% of homozygotes develop lung cancer relative to 6.7% in wild-type controls

immune system
increased T cell derived lymphoma incidence ( J:210264 )
• 58.3% of homozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype

hematopoietic system
increased T cell derived lymphoma incidence ( J:210264 )
• 58.3% of homozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype




Genotype
MGI:5699403
ht2
Allelic
Composition		 Ndrg2tm1Kmori/Ndrg2+
Genetic
Background		 involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndrg2tm1Kmori mutation (0 available); any Ndrg2 mutation (27 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype

Ndrg2tm1Kmori/Ndrg2+ mice are susceptible to tumour formation

mortality/aging
decreased survivor rate ( J:210264 )
• survival rate is reduced at >15 months of age, and declines thereafter
• only ~30% of heterozygotes survive to 24 months of age
premature death ( J:210264 )
• heterozygotes exhibit a significantly shorter lifespan than wild-type controls

neoplasm
increased tumor incidence ( J:210264 )
• 64.5% of heterozygotes exhibit spontaneous tumor development of various types, including T-cell lymphomas, relative to 26.7% in wild-type controls
increased gastrointestinal tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop intestinal cancer relative to 0% (none) in wild-type controls
increased T cell derived lymphoma incidence ( J:210264 )
• 38.7% of heterozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype
increased pancreas tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop pancreatic cancer relative to 0% (none) in wild-type controls
increased testis tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop testicular cancer relative to 0% (none) in wild-type controls
increased skin tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop skin tumor relative to 0% (none) in wild-type controls
increased hepatocellular carcinoma incidence ( J:210264 )
• 3.2% of heterozygotes develop hepatic cancer relative to 0% (none) in wild-type controls
• H&E staining revealed a large sheet of hepatic cords consisting of several hepatocytes of variable nuclei and cell sizes; the nuclei of the carcinoma cells appear hyperchromatic with prominent nucleoli
• liver histopathology showed massive infiltration of large atypical lymphoid cells in portal areas and the sinus; tumor cells are CD3+CD4+CD8- and B220-
increased lung carcinoma incidence ( J:210264 )
• 12.9% of heterozygotes develop lung cancer relative to 6.7% in wild-type controls
• H&E staining of bronchoalveolar carcinomas revealed a well-circumscribed mass of a solid sheet of neoplastic cells containing hyperchromatic nuclei with signs of frequent mitosis and an indistinct basophilic cytoplasm
increased brain tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop brain tumor relative to 0% (none) in wild-type controls

cellular
increased fibroblast proliferation ( J:210264 )
• heterozygous mutant MEFs exhibit an increased cell proliferation rate that is intermediate between that of wild-type and homozygous mutant MEFs

integument
increased skin tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop skin tumor relative to 0% (none) in wild-type controls

liver/biliary system
increased hepatocellular carcinoma incidence ( J:210264 )
• 3.2% of heterozygotes develop hepatic cancer relative to 0% (none) in wild-type controls
• H&E staining revealed a large sheet of hepatic cords consisting of several hepatocytes of variable nuclei and cell sizes; the nuclei of the carcinoma cells appear hyperchromatic with prominent nucleoli
• liver histopathology showed massive infiltration of large atypical lymphoid cells in portal areas and the sinus; tumor cells are CD3+CD4+CD8- and B220-

respiratory system
increased lung carcinoma incidence ( J:210264 )
• 12.9% of heterozygotes develop lung cancer relative to 6.7% in wild-type controls
• H&E staining of bronchoalveolar carcinomas revealed a well-circumscribed mass of a solid sheet of neoplastic cells containing hyperchromatic nuclei with signs of frequent mitosis and an indistinct basophilic cytoplasm

digestive/alimentary system
increased gastrointestinal tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop intestinal cancer relative to 0% (none) in wild-type controls

reproductive system
increased testis tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop testicular cancer relative to 0% (none) in wild-type controls

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:210264 )
• 38.7% of heterozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype
increased pancreas tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop pancreatic cancer relative to 0% (none) in wild-type controls
increased testis tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop testicular cancer relative to 0% (none) in wild-type controls

nervous system
increased brain tumor incidence ( J:210264 )
• 3.2% of heterozygotes develop brain tumor relative to 0% (none) in wild-type controls

immune system
increased T cell derived lymphoma incidence ( J:210264 )
• 38.7% of heterozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype

hematopoietic system
increased T cell derived lymphoma incidence ( J:210264 )
• 38.7% of heterozygotes develop malignant lymphomas relative to 13.3% in wild-type controls
• the infiltrating lymphoid cells are CD3+CD4+CD8- indicating a mature helper T-cell phenotype




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/19/2024
MGI 6.24 		The Jackson Laboratory